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Abstract
Background: Hereditary Angioedema (HAE), a rare genetic disease, manifests as intermittent, painful attacks of
angioedema. Attacks vary in frequency and severity and include skin, abdominal and life-threatening laryngeal swellings.
This study aimed to develop a patient reported outcome (PRO) tool for the assessment of HAE attacks, including their
management and impact on patients’ lives, for use in clinical studies, or by physicians in general practice.
Methods: The results of open-ended face to face concept elicitation interviews with HAE patients in Argentina
(n = 10) and the US (n = 33) were used to develop the first draft questionnaire of the HAE patient reported outcomes
questionnaire (HAE PRO). Subsequently, in-depth cognitive debriefing interviews were performed with HAE patients in
the UK (n = 10), Brazil (n = 10), Germany (n = 11) and France (n = 12). Following input from eight multinational clinical
experts further cognitive interviews were conducted in the US (n = 12) and Germany (n = 12). Patients who experienced
abdominal, cutaneous or laryngeal attacks of varying severity levels were included in all rounds of interviews. Across
the rounds of interviews patients discussed their HAE attack symptoms, impacts and treatments. Cognitive debriefing
interviews explored patient understanding and relevance of questionnaire items. All interviews were conducted face to
face following a pre-defined semi-structured interview guide in the patient’s native language.
Results: Patients reported a variety of HAE symptoms, attack triggers, warning signs, attack impacts and treatment
options which were used to develop the HAE PRO. The HAE PRO was revised and refined following input from
patients and clinical experts. The final 18-item HAE PRO provides an assessment of the HAE attack experience including
symptoms, impacts, treatment requirements, healthcare resource use and loss of productivity caused by HAE attacks.
Conclusions: Patient and expert input has contributed to the development of a content valid questionnaire that
assesses concepts important to HAE patients globally. HAE patients across cultures consider the HAE PRO a relevant
and appropriate assessment of HAE attacks and treatment.
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Hereditary angioedema (HAE) due to C1-Inhibitor defects
is a rare genetic disease that manifests as unpredictable
recurring attacks of painful angioedema (swelling) [1–3].
The disease occurs in two main phenotypic variants: Type
I (occurring in approximately 80-85 % of patients) is char-
acterized by a decrease in the formation of C1-INH to
about 10-30 % of normal [1]. Type II (approximately
15-20 % of patients) is manifested by production of
normal or increased levels of a non-functional C1-INH
protein that is antigenically intact [4]. The prevalence
of HAE is estimated at 1:50,000 [5].
HAE attacks can occur in various locations of the body
but are categorized into three main types: attacks affecting
the skin (cutaneous attacks), attacks affecting the gastro-
intestinal system (abdominal attacks) and attacks affecting
the larynx (laryngeal swellings) [4]. Cutaneous attacks
are most frequent in occurrence, followed by abdominal
attacks, which are known to be extremely painful and
laryngeal attacks, which can be fatal if untreated [1, 4, 6].
Attack swellings develop slowly over 36 h and resolve
within two to five days [3, 4]. HAE attacks can cause se-
vere discomfort, pain and disability to patients resulting in
emotional distress and impacting the patient’s ability to
perform their daily activities [7, 8].
A patient reported outcome (PRO) is a measurement
report that comes directly from the patient without the
input or interpretation of a clinician or any other health
professional [9]. PRO measures are important in clinical
and registry studies because they provide insight into the
patient perspective of the disease experience, and they
allow assessment of symptoms and impacts that cannot
be measured objectively though the use of traditional
biological assessments [10]. This is especially the case in
rare disorders, where the disease experience may not be
well understood. In HAE particularly, PRO measures are
beneficial as the fluctuating nature of HAE attacks can
be difficult for physicians to monitor, and for symptoms
such as pain, the patient is often the best reporter of the
symptoms. Thus in these situations the patient perspec-
tive is imperative. When developing a PRO measure, it
is essential to first ensure that the measure covers the is-
sues that are relevant to the patients themselves and to
ascertain whether the patients understand the ques-
tionnaire [9, 11]. Such insights are gathered through
qualitative research with patients with the target disease.
Without such research, there is a danger that the instrument
will be developed to measure concepts that are irrelevant to
or misunderstood by patients, which could subsequently
yield data that is difficult to interpret.
The identification of bradykinin as the mediator of acute
HAE attacks [2] has led to the introduction of new treat-
ments for HAE patients. The approval of new treatments
and the need for long term monitoring of safety through
registry studies has highlighted the requirement for appro-
priate HAE assessment tools.
The Icatibant Outcome Survey (IOS) is an international,
open-ended patient registry inclusive of all patients who are
receiving, or are candidates for, subcutaneous treatment
with icatibant, primarily patients with hereditary angio-
edema [HAE] types I and II [2, 12, 13]. The inclusion
of a single instrument assessing all aspects of HAE was
proposed as the optimum data collection tool for the
study. Thus, the development of a single tool assessing
all elements of HAE attacks appropriate for use within
the IOS was undertaken.
Published studies have cited the use of PRO measures
specific to HAE. Vernon et al. presented the psychometric
validation of two PRO measures for use in HAE [14].
However, these two measures are specific to symptom as-
sessment only and therefore, would not be appropriate for
the assessment of all elements of a HAE attack including:
attack duration, triggers, warning signs, location of attack,
symptoms, impacts, resource use and treatment, as is the
aim of IOS. Wilson et al. published a study using a web-
based survey of HAE patients to determine the economic
costs associated with HAE [8]. This PRO, whilst covering
a number of relevant concepts, was designed to assess
economic burden associated with HAE based on completion
at a single timepoint rather than long-term assessments of
all elements of HAE attacks. Given that these previously
published measures were not considered appropriate
for use in the IOS, the development of a new HAE specific
PRO tool was undertaken.
The objective of this work was to develop a PRO ques-
tionnaire that assesses all aspects of a HAE attack. The
specific objective of the first stage of the study was to
elicit concepts important and relevant to HAE patients.
The objectives of the later stages were to develop a PRO
questionnaire assessing all relevant HAE attack concepts
and to confirm the face and content validity of the HAE
PRO questionnaire.
Methods
The development of the HAE PRO was conducted over
four stages involving interviews with HAE patients and
consultation with expert HAE clinicians (Fig. 1). At all
stages patients were recruited through specialist HAE treat-
ment centers and via patient recruitment agencies and
support groups.
Study participants
For the initial concept elicitation phase of the study, male
and female patients aged over 18 years were included if
they had a clinician confirmed diagnosis of HAE Type I or
II and had experienced a cutaneous, abdominal and/or la-
ryngeal attack within the four weeks prior to screening.
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The patients were required to be able to complete an
interview in their native language (US-English or Spanish
for Argentina). Patients were excluded from the study if
they fulfilled any of the following criteria: diagnosis of
angioedema other than HAE, for example acquired an-
gioedema (AAE); a life-threatening health condition other
than HAE; and great difficulty hearing or reading. The
same inclusion criterion was used for the second set of
concept elicitation interviews and the cognitive debriefing
phase of the study.
For the second set of concept elicitation interviews
patients were only required to have had a HAE attack
within the six months prior to the interview. This criterion




The first stage of the project involved conduct of quali-
tative interviews with HAE patients in the US and
Argentina. The aim of these interviews was to elicit
concepts important to patients to include in the HAE
PRO. The open-ended interviews were conducted with
10 patients from one site in Argentina and 22 patients
from six sites in the US.
To ensure patients who had experienced a variety of
HAE attack types were included in the study the follow-
ing recruitment quotas were set: Recruitment of up to
10 patients who experienced a cutaneous attack in the four
weeks prior to the study, Recruitment of up to 10 patients
who experienced an abdominal attack in the four weeks
Fig. 1 Development of the HAE PRO
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prior to the study and Recruitment of four to eight pa-
tients who experienced a laryngeal attack in the four
weeks prior to the study. During the interview patients
described HAE attack symptoms and how having HAE
affects their life, they also discussed their HAE treatment.
Patients described HAE attack triggers and how and when
they know a HAE attack is coming on (warning signs, pro-
dromal symptoms). Where possible these discussions were
conducted in an open-ended manner with the aim to elicit
spontaneous responses.
Data from a second set of 11 interviews with HAE pa-
tients recruited from two sites in the US provided fur-
ther evidence of relevant concepts to include in the draft
PRO measure. At each study site quotas were set so that
at least one patient whose most recent attack was abdom-
inal, cutaneous and laryngeal respectively were targeted for
recruitment. Further data pertaining to attack symptoms,
impacts, triggers, warning signs and treatments was gath-
ered as part of these interviews.
Using concepts elicited from the two set of interviews
a draft questionnaire was developed. The aim of this ques-
tionnaire was to assess relevant aspects associated with
HAE attacks including the attack experience (8 items),
HAE attack treatments (4 items) and resource use (4 items)
associated with HAE attacks and its treatment.
Initial cognitive debriefing interviews
To test the face and content validity of the draft HAE
PRO, in-depth, open-ended and cognitive debriefing in-
terviews were performed with HAE patients in the UK
(n = 10), Brazil (n = 10), Germany (n = 11) and France
(n = 12). Interviews were conducted in the local language
of each country. In each country at least two patients were
recruited for whom their most recent attack was abdom-
inal and cutaneous, respectively, and at least one patient
for whom their most recent attack was laryngeal. At this
stage, to facilitate recruitment, there was no time limit in
which patients had to have had an attack prior to the
interview. These cognitive debriefing interviews were di-
vided into two parts. In the first part patients discussed
their experience of HAE in an open-ended manner. The
second part of the interview involved cognitive debriefing
of the draft PRO to assess patient understanding and rele-
vance of questionnaire items, instructions and response
options.
Based on patient feedback from this first set of cognitive
debriefing interviews revisions were made to the question-
naire items and response options during an international
harmonization meeting. Revisions included the addition
of nine sub-concepts to ensure inclusion of all concepts
relevant to HAE attacks and adaptations to ensure that all
concepts were culturally appropriate across countries. The
completion of phase two of the research resulted in an
instrument that focuses on the symptomatology, treat-
ment and resource use associated with HAE attacks.
Expert input
Following the first set of cognitive debriefing interviews
a panel of international HAE experts (n = 8) reviewed
the questionnaire with the aim of making the HAE PRO
more complete and suitable for use internationally. Fol-
lowing the expert input, the HAE PRO was updated to
include assessment of a wider range of HAE treatments
(reflective of available treatments in each country) and
symptomatology associated with HAE attacks.
Second round of cognitive debriefing interviews
To confirm the face and content validity and cultural
relevance of the revised HAE PRO, further cognitive
debriefing interviews were conducted in the US (n = 12)
and Germany (n = 12). During the interviews patients
discussed their understanding of the HAE PRO instruc-
tions, items and response options and provided feedback
on the relevance of items and ease of questionnaire com-
pletion. Based on comments from the patients in this final
set of interviews and considering feedback from earlier
rounds of interviews minor revisions were made to the
questionnaire to facilitate patient understanding of the in-
structions and response options on the HAE PRO. A final
instrument and conceptual framework were developed.
Ethics approval
The study protocols for each phase of the project were
submitted to relevant centralized or local ethics review
boards, approval was granted for all study phases. All
patients completed an informed consent form before
undertaking any study activities. Across the individual
stages of the study different institutional review boards
were involved in the study approvals. These review
boards included local site review boards across the US
and Argentina, Copernicus Group IRB in the US and the
Freiburger Ethik-Komission International in Germany.
Qualitative analysis of interviews
Across all four project stages interviews were audio re-
corded and transcribed verbatim. Interview transcripts
were translated into English where relevant. Interviews
were qualitatively analyzed using Atlas. Ti software [15].
Atlas software allows traditional qualitative analysis of
transcripts, but facilitates easier break-down of qualitative
data into groups (for example, issues by gender or attack
type). Analysis of the concept elicitation interviews fo-
cused on identifying HAE concepts important to patients
and the language patients’ use to describe those concepts.
When analyzing the cognitive debriefing interviews the
focus was on confirming patient understanding and inter-
pretation of items, instructions and response options of
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the HAE PRO. As HAE is a rare condition and patients
could be identified from individual descriptive information
such as interview location and age all quotes presented in
this document specify patient gender only. Across all pro-
ject stages demographic and clinical data were collected
and descriptively analyzed. No other quantitative analysis
was conducted as part of this study.
Translation and linguistic validation
Through all phases of HAE PRO development, consider-
ation was given to ensuring the instrument was appro-
priate for use across different countries. The instrument
has been translated and culturally adapted for use in UK-
English, German, French, Italian, Spanish for Argentina,
German for Austria and Portuguese for Brazil. At all
phases translation has been conducted using two forward,
one backwards translation methodology, where two inde-
pendent forward translations are harmonized and then
back-translated to confirm accuracy of the translation.
Across all of the translations conceptual equivalence
was a key consideration.
Results
Stage 1: Initial concept elicitation interviews
The demographic and clinical characteristics of the con-
cept elicitation sample can be found in Table 1.
A number of concepts emerged from the concept elicit-
ation interviews related to attack triggers, warning signs
experienced before attacks, attack symptoms, impacts,
attack treatments and coping methods (Fig. 2). Further
detail of each concept is presented below.
Attack triggers
Examples of attack triggers reported by patients included
stress, other illnesses, particularly infections, physical ac-
tivity, surgery, physical trauma and hormonal changes in
women (Fig. 2). While some patients were very certain
about what triggered their attacks, others stated that at-
tacks sometimes occur with no known trigger.
Warning signs of HAE attacks
As HAE patients become experienced with their disease
they learn to recognize the early warning signs of an at-
tack (Fig. 2). The patients interviewed stated these symp-
toms appear two to three days before the attack occurs.
Examples of warning signs reported include red rings or
spots on the skin in the area in which the attack will
occur, an itching or tingling sensation in the skin, tight
skin, sore joints, a feeling of nausea or a gassy feeling in
the stomach and feeling tired. As with triggers, some
patients stated that while sometimes they experience rec-
ognized warning signs, on other occasions an attack starts
without any prior warning.
Cutaneous HAE attacks
HAE patients described cutaneous attack symptoms in-
cluding pain or discomfort caused by skin swelling, itching
or irritation on the skin and a redness or rash around the
area of swelling. The patients also described their skin
feeling tight or tender and feeling like the skin is ‘burning’.
The reported frequency of cutaneous attacks varied from
every few days to once a year. The patients reported that
cutaneous attack duration ranged from a few hours to
four days; most patients said that the attacks normally last
between two and four days. As cutaneous attacks can be
relatively mild some patients stated that the duration of
the attack can vary based on whether the patient decides
to treat it or not. A number of different locations for cuta-
neous attacks were reported; the most common being the
hands, feet, genitals, face (including lips), legs and arms.
The patients also reported skin swelling affecting the outer
skin of the abdomen which was seen as different to ab-
dominal attacks affecting the gastrointestinal tract.
Abdominal HAE attacks
The most commonly reported abdominal symptoms were
pain, vomiting, swelling, bloating, nausea, diarrhea and
cramping. The reported frequency of abdominal attacks
was slightly less than cutaneous attacks, ranging from
weekly attacks to attacks occurring every month or every
two months. Consistent with cutaneous attacks the pa-
tients stated that abdominal attacks usually last between
two to three days; although some attacks resolve as
quickly as 12 h while others last up to a week.
Laryngeal HAE attacks
Four key laryngeal attack symptoms were consistently
described: difficulty breathing, difficulty swallowing, throat
swelling and voice change. Laryngeal attacks were reported
as less frequent than other HAE attack types. Patients re-
ported only having one or two laryngeal attacks in their
life, or only having this type of attack every three or four
years. Consistent with other types of HAE attacks, the
patients interviewed reported that laryngeal attacks last
between a few hours to three or four days.
Attack severity
While all three types of attack (abdominal, cutaneous and
laryngeal) can vary from mild to severe, generally, patients
defined attack severity in terms of the type of attack expe-
rienced, the symptom’s impact on daily life (i.e., the need
to stop doing things) and the need to seek medical care.
All laryngeal attacks were considered to be severe; signs
and early symptoms of a laryngeal attack led patients to
immediately seek medical care since they could potentially
experience significant respiratory distress. Laryngeal at-
tacks were viewed as most severe given that they are
life threatening. While not as life-threatening as
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Table 1 Demographic and Clinical Characteristics of the Concept Elicitation Samples (N = 43)
Demographic or clinical characteristic Initial Concept Elicitation Sample Second Concept Elicitation Sample





Min, Max 20-75 19-54
Gender (n) (%)
Male 9 (28.1) 5 (45.5)
Female 23 (71.9) 6 (54.5)
How would you rate your health in general (n) (%)
Excellent 1 (3.1) 2 (18.2)
Very good 11 (34.3) 4 (36.4)
Good 12 (37.5) 3 (27.3)
Fair 5 (15.6) 1 (9.1)
Poor 3 (9.4) 1 (9.1)
Clinical Characteristics
Age diagnosed with hereditary angioedema
Mean 20.3 23.6
Median 20.5 23
Min, Max 1.5-47 7-44
Type of HAE (n) (%)
Type I 28 (87.5) 11 (100)
Type II 4 (12.5) 0 (0)
Type of most recent attack n (%)
Cutaneous 14 (43.8) 5 (45.5)
Abdominal 12 (37.5) 5 (45.5)
Laryngeal 2 (6.3) 0 (0)
Cutaneous and abdominal 3 (9.4) 1 (9)
Cutaneous, abdominal and laryngeal 1 (3.3) 0 (0)
How were you diagnosed with HAE (n) (%)
General Practitioner 4 (3.9) 0 (0)a
HAE specialist 14 (43.8) 5 (45.5)
Diagnosed because other family members had the condition 13 (40.6) 4 (36.6)
Other: 1 (3.1) 0 (0)
Allergist 3 (9.4) 0 (0)
Gastroenterologist 1 (3.1) 0 (0)
National Institutes of Health (NIH) 1 (3.1) 0 (0)
Immunologist 1 (3.1) 0 (0)
Pediatrician 1 (3.1) 0 (0)
Research clinic 1 (3.1) 0 (0)
Research physician 0 (0) 1 (9.1)
Physician – internist 0 (0) 1 (9.1)
Rheumatologist 0 (0) 1 (9.1)
an value adds up to more than 11 as one patient reported more than one method of diagnosis
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laryngeal attacks, abdominal attacks were considered
moderately severe to severe dependent on the level of
pain and symptoms experienced. Abdominal attacks were
considered more severe than cutaneous attacks. HAE pa-
tients reported that skin attack severity varies due to the
location of the attack. All cutaneous attacks were consid-
ered less painful than abdominal attacks, but severity is
dependent on how the attack affects the patient’s ability to
function.
Impact of HAE attacks
As demonstrated in Fig. 2, HAE has a considerable im-
pact on patients’ lives. Patients described a number of
impacts that could be grouped into the following sub-
concepts: physical impacts, impact on ability to perform
usual role, emotional and social impacts, impact on rela-
tionships, impact on appearance and morbidity. HAE
patients described more severe attacks having a greater
impact as they are debilitating, causing the patient to stay
at home and miss work and other activities including so-
cial plans. Milder attacks, dependent on location, cause
less disruption to the patients’ lives. Some patients added
that they have learned to live with HAE and try not to let
attacks affect their life.
Attack treatment
The patients stated that they do not always seek treatment
if the attack is mild or manageable because they know
Fig. 2 HAE conceptual model based on evidence generated from concept elicitation interviews
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it will resolve eventually. Other patients stated that they
treat themselves at home if they have appropriate treat-
ment available, or just take pain medication to relieve
symptoms. For more severe attacks, patients seek treatment
from their doctor, and particularly in the case of laryngeal
attacks seek emergency treatment. Some patients described
experiences where they had tried to seek treatment for
an attack but were given inappropriate treatment because
doctors were unfamiliar with HAE. In some cases treating
doctors even tried to do surgery to treat abdominal
attacks, actually exacerbating the attack. The patients
described specific treatments they had taken for their
HAE as presented in Fig. 2.
Conceptual model
Data generated from the concept elicitation interviews
was used to develop a conceptual model for HAE and
acute attacks (Fig. 2). The conceptual model provides a
summary of HAE attack symptoms, impact domains, at-
tack triggers and warning signs, coping methods employed
by patients and HAE treatments. The conceptual model
demonstrates the complexity of HAE and illustrates the
need to consider all aspects of the attack and not just
symptoms.
Stage 2: First round of cognitive debriefing interviews
The demographic and clinical characteristics of the ini-
tial cognitive debriefing sample can be found in Table 2.
Table 3 presents the symptoms assessed by the HAE
PRO that were spontaneously reported by patients and
the additional symptoms reported that were not specific-
ally included in the first version of the HAE PRO. All
symptoms measured by the HAE PRO questionnaire were
mentioned by at least three patients. The most commonly
mentioned symptoms were assessed by the HAE PRO, in-
cluding abdominal pain (n = 30), skin swelling (n = 28),
vomiting (n = 15), diarrhea (n = 13), nausea (n = 11) and
skin pain (n = 11). A number of additional symptoms were
spontaneously reported by patients. Of these symptoms, it
was agreed that difficulty breathing (n = 5) and constipa-
tion (n = 3) should be included in the HAE PRO due to
perceived importance to patients and clinical relevance.
While a number of other symptoms were reported they
were considered similar to other symptoms already in-
cluded in the questionnaire, or distal, secondary symp-
toms that were not necessary to add.
Table 4 presents the HAE attack triggers assessed by
the HAE PRO that were spontaneously reported during
the interview, and the additional triggers reported by pa-
tients that were not specifically included in the first ver-
sion of the HAE PRO. All triggers included in the HAE
PRO questionnaire were confirmed by at least one patient.
From the additional triggers mentioned by patients, tired-
ness (n = 8) was added to the revised questionnaire.
Coverage of HAE warning signs included in the draft
HAE PRO and reported by patients spontaneously can
be found in Table 5. All warning signs presented on the
HAE PRO were supported by the patients. From the
additional attack warning signs mentioned, red rings on
the skin (n = 3) was added to the questionnaire as this
was considered by patients to be an important warning
sign of an attack.
Cognitive debriefing of the HAE PRO indicated that
on the whole, the instrument was well understood by
HAE patients. The patients interpreted the items and re-
sponse options consistently and found that the HAE PRO
accurately captured their experiences of HAE attacks and
the treatment they receive. Although the HAE PRO was
well received, patients made recommendations to further
improve the face and content validity of the HAE PRO.
These changes were implemented to further strengthen
the face and content validity of the instrument.
Stage 3: Expert input
Between the first and second set of cognitive debriefing
interviews a panel of international HAE experts provided
input to the questionnaire. Based on this input the HAE
PRO was updated to include assessment of a wider range
of HAE treatments and symptomatology, specifically a
number of items assessing preventative HAE treatments
were added to the instrument.
Stage 4: Second round of cognitive debriefing interviews
Details of the demographic and clinical characteristics of
the second cognitive debriefing sample can be found in
Table 6.
Consistent with the first round of cognitive debriefing
interviews, overall, the HAE PRO was relevant to HAE
patients and deemed appropriate for their attack experi-
ence. While there were some problems knowing how to
complete some of the items, the majority of these were
likely due to patients completing the questionnaire out
of context of a study, not in the intended mode of ad-
ministration and when they had not necessarily had an
attack in the days prior to the interview. Although the
majority of patients were happy with the HAE PRO there
were some items, instructions and response options that
caused patients a considerable amount of difficulty therefore
some revisions were made to the instrument to enhance the
understandability and relevance of the instructions, items
and response options of the instrument.
Final HAE PRO
Evidence from the second round of cognitive debriefing
interviews was considered alongside patient input from
the previous phases of the research and a final instrument
was created. Figure 3 presents the conceptual framework
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Table 2 Demographic and Clinical Characteristics of the Initial Cognitive Debriefing Sample (N = 43)
UK (n = 10) Brazil (n = 10) Germany (n = 11) France (n = 12) Total (n = 43)
Demographic Characteristics
Age of patient
Mean 46 38 38 36 39
Min - Max 20-66 24-66 18-65 20-60 18 - 66
Gender n (%)
Male 2 (20) 2 (20) 5 (45) 6 (50) 15 (35)
Female 8 (80) 8 (80) 6 (55) 6 (50) 28 (65)
Highest education levela n (%)
General Certificate of Secondary Education (GCSE) or less 6 (60) 0 1 (9) 0 7 (16)
Advanced (A) Levels 2 (20) 6 (60) 1 (9) 1 (8) 10 (23)
Vocational qualification or Apprenticeship 0 0 5 (45) 1 (8) 6 (14)
University or College degree 2 (20) 2 (20) 4 (36) 4 (33) 12 (28)
Post-graduate degree or qualification 0 2 (20) 0 6 (50) 8 (19)
Clinical Characteristics
Type of Hereditary Angioedema n (%)
Type I N/Ab 9 (90) 9 (82) 9 (75) 27 (82)
Type II N/A 1 (10) 2 (18) 1 (8) 4 (12)
Missing data N/A 0 0 2 (17) 2 (6)
Type of Hereditary Angioedema attack(s) experienced in
the past six months n (%)
Cutaneous edema (skin swelling) 9 (90) 8 (80) 10 (91) 10 (83) 37 (86)
Abdominal edema (internal swelling) 7 (70) 6 (60) 9 (82) 9 (75) 31 (72)
Laryngeal edema (throat swelling) 5 (50) 2 (20) 3 (27) 2 (17) 12 (28)
Type of Hereditary Angioedema attack(s) experienced most
recently n (%)
Cutaneous edema (skin swelling) 5 (50) 6 (60) 7 (64) 8 (67) 26 (60)
Abdominal edema (internal swelling) 7 (70) 3 (30) 6 (55) 7 (58) 23 (53)
Laryngeal edema (throat swelling) 2 (20) 1 (10) 0 0 3 (7)
Days since last attack
Mean 44 33 17 75 43
Min - Max 0 - 172 4 - 133 0 - 84 9 - 204 0 - 204
Hereditary Angioedema diagnosis by n (%)
General Practitioner (GP) 3 (30) 0 1 (9) 0 4 (9)
Hereditary Angioedema Specialist 3 (30) 5 (50) 5 (45) 3 (25) 16 (37)
Diagnosed because other family members had the condition 2 (20)c 1 (10) 4 (36) 5 (42) 12 (28)
Diagnosis due to other tests/problems 2 (20) 0 1 (9) 0 3 (7)
Dermatologist 1 (10) 0 0 1 (8) 2 (5)
Pediatrician 0 0 0 1 (8) 1 (2)
Allergist 0 2 (20) 0 1 (8) 3 (7)
Emergency Physician 0 1 (10) 0 1 (8) 2 (5)
Neurologist 0 1 (10) 0 0 1 (2)
aEducational levels are provided as described for the English interviews. The levels were translated and made culturally equivalent for each country
bData for Type of HAE not available for UK patients as this was a clinician reported characteristic, no clinician reported data was collected in the UK
cOne patient chose diagnosed by GP and diagnosed because other family member had the condition
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for the final instrument with patient quotes confirming
the relevance of the HAE PRO. The concepts in the model
are color coded to demonstrate the evolution of the in-
strument over time.
Discussion
Evidence generated from the concept elicitation phase
demonstrated the complex, multi-faceted nature of HAE.
Not only do patients experience different symptoms de-
pending on attack type, their lives are considerably
impacted by the disease. Patients have to manage living
with an unpredictable genetic condition whilst coping
with a lack of awareness of the disease by clinicians and
members of the public.
Given the complex nature of HAE it was clear that
multiple HAE concepts need to be assessed to achieve a
holistic assessment of HAE attacks and their treatment.
As there were no existing measures assessing a range of
factors specific to HAE including triggers, warning signs,
symptoms, impact and resource use the development of
an instrument assessing a range of HAE concepts was
undertaken.
To ensure all concepts important to patients were cap-
tured concept elicitation interviews were conducted with
HAE patients in two countries. The concept elicitation
interviews highlighted that the patient experience of HAE
extends beyond HAE attacks alone. Evidence from the
concept elicitation interviews allowed a comprehensive
conceptual model to be developed that captures HAE at-
tacks in their entirety, including concepts such as symp-
toms, impacts, treatment and resource use associated with
HAE.
Face and content validity of the instrument was tested
through cognitive debriefing interviews with HAE patients
in four countries. Analysis of the concept coverage of
the HAE PRO questionnaire confirmed that all con-
cepts included in the measure are relevant to HAE pa-
tients across different attack types. Although, the HAE
patients highlighted additional concepts above those
already captured by the instrument, most of the additional
symptoms, triggers or warning signs described by patients
were seen as similar to those already included, or second-
ary symptoms captured by existing items on the question-
naire. However, where it was considered clinically relevant
or there was substantial patient support additional
Table 4 Assessment of coverage of HAE attack triggers by the
HAE PRO
Triggers assessed by HAE PRO
and mentioned by patients
Additional triggers mentioned
by patients (n = 43)
Emotional distress (n = 18) Tiredness (n = 8)
Physical trauma (n = 15) Temperature (low, high,
sudden change) (n = 4)
Hormones (n = 12) Shoes (n = 3)
Pressure on the skin (n = 11) Dental treatment (n = 2)
Illness/ infection (n = 10) Insect bite (n = 2)
None (n = 7) Sunlight (n = 1)
Stress (n = 6) Sport (n = 1)
Sitting or standing (n = 5) Repeated movement (n = 1)
Food or drink (n = 4) Smoke (n = 1)
Chemicals (n = 2)
Medication (n = 1)
Table 5 Assessment of coverage of HAE attack warning signs
by the HAE PRO
Warning signs assessed by HAE
PRO and mentioned by patients
Additional warning signs
mentioned by patients (n = 43)
Skin redness (n = 13) Pain (n = 4)
Irritability (n = 11) Itchiness (n = 4)
Nausea (n = 8) Burning (n = 4)
Skin sensation (n = 7) None (n = 4)
Tiredness (n = 7) Feeling of butterflies (n = 3)
Skin Tightness (n = 6) Swelling (n = 3)
Aggressiveness (n = 3) Red rings on the skin (n = 3)
Sensitivity to noise (n = 3) Stress (n = 2)
Hunger (n = 2) Headaches (n = 2)
Prickling (n = 1) Thirst (n = 2)
Difficulty breathing (n = 2)
Numbness (n = 2)
Table 3 Assessment of coverage of HAE symptoms by the HAE
PRO
Symptoms assessed by HAE PRO
and mentioned by patients
Additional symptoms mentioned
by patients (n = 43)
Abdominal pain (n = 30) Stomach/bowel swelling (n = 13)
Skin swelling (n = 28) Spasms/cramping (n = 8)
Vomiting (n = 15) Tiredness (n = 8)
Nausea (n = 11) Stomach ache (n = 6)
Diarrhoea (n = 13) Difficulty breathing (n = 5)
Skin pain (n = 11) Sore skin (n = 4)
Erythema (skin redness) (n = 8) Constipation (n = 3)
Skin irritation (n = 5) Tingling (n = 3)
Voice change (n = 4) Tight skin (n = 3)
Difficulty swallowing (n = 3) Red rings (n = 2)
Itching (n = 2)
Burning (n = 2)
Discomfort (n = 2)
Passing out/drop in blood
pressure (n = 2)
Tight esophagus (n = 2)
Throat pain (n = 2)
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concepts were added. Where patients experienced trig-
gers, warning signs or symptoms not directly assessed
they were satisfied that these could be reported under
‘other’. This evidence from the open-ended aspects of the
initial cognitive debriefing interviews supports the content
validity of the HAE PRO.
While the questionnaire was generally well understood
and interpreted correctly and consistently, there were
some aspects of the items and response options that
caused confusion for the patients during the first round of
cognitive debriefing interviews. As a follow up to the cog-
nitive debriefing study an international harmonization
meeting was held involving representatives from each
language in which the cognitive debriefing study was
performed. In this meeting each item was discussed
and patient specific feedback was considered. Revisions
to all relevant aspects of the questionnaire were made
to increase understanding and relevance of all of con-
cepts and items included in the questionnaire, without
adding significant respondent burden. These revisions
Table 6 Demographic and Clinical Characteristics of the Second Cognitive Debriefing Sample (N = 24)
Germany (n = 12) US (n = 12) Total (n = 24)
Demographic Characteristics
Age of patient
Mean 40.6 42.5 41.5
Min - Max 23-61 21-60 21-61
Gender n (%)
Male 3 (25) 6 (50) 9 (37.5)
Female 9 (75) 6 (50) 15 (62.5)
Highest education level n (%)
Some high school 1 (8.3) 0 1 (2.4)
High school diploma or GED 2 (16.7) 3 (25) 5 (20.8)
Some years of college 3 (25) 3 (25) 6 (25)
Vocational qualification or Apprenticeship 5 (41.7) 1 (8.3) 6 (25)
University or College degree 1 (8.3) 4 (33.3) 5 (20.8)
Post-graduate degree or qualification 0 1 (8.3) 1 (4.2)
Clinical Characteristics
Type of Hereditary Angioedema n (%)
Type I 11 (91.7) 12 (100) 23 (95.8)
Type II 1 (8.3) 0 1 (4.2)
Type of Hereditary Angioedema attack(s) experienced in the past six monthsa n (%)
Cutaneous edema (skin swelling) 10 (83.3) 11 (91.6) 21 (87.5)
Abdominal edema (internal swelling) 8 (66.7) 7 (29.2) 15 (62.5)
Laryngeal edema (throat swelling) 2 (16.6) 2 (16.6) 4 (16.7)
Type of Hereditary Angioedema attack(s) experienced most recentlya n (%)
Cutaneous edema (skin swelling) 9 (75) 8 (66.7) 17 (70.8)
Abdominal edema (internal swelling) 5 (41.6) 5 (41.6) 10 (41.6)
Laryngeal edema (throat swelling) 0 (0) 0 (0) 0 (0)
Days since last attack
Mean 784 64.25 424
Min – Max 1-8604 3-405 1-8604
Hereditary Angioedema diagnosis by n (%)
General Practitioner (GP) 1 (8.3) 2 (16.7) 13 (12.5)
Hereditary Angioedema Specialist 7 (58.3) 5 (41.7) 12 (50)
Diagnosed because other family members had the condition 4 (33.3) 4 (33.3) 8 (33.3)
Other 0 (0) 1 (8.3) 1 (4.2)
aPatients could select more than one type of attack
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Fig. 3 HAE PRO conceptual framework
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further support the face and content validity and global
relevance of the questionnaire.
The World Allergy Organization (WAO) Guideline
for the Management of HAE [16] and the Hereditary
Angioedema International Working Group (HAWK)
consensus report provide evidence-based recommenda-
tions regarding management approaches for HAE patients.
These documents, published in 2012, were important con-
siderations to ensure that the questionnaire addresses the
key issues for HAE patients and physicians [17]. As these
documents were published after the initial development of
the HAE PRO, to confirm the clinical relevance of the in-
strument, expert HAE clinicians reviewed the HAE PRO
against the WAO Guideline for the Management of HAE
and the HAWK consensus report.[16, 17] The clinical
experts further expanded the conceptual coverage of the
HAE PRO to ensure complete assessment of the HAE-
related issues that may not have been initially raised by the
patients themselves, but that were deemed to be clinically
relevant to HAE. A key addition was the inclusion of items
assessing preventative HAE treatment as preventative
treatment options have changed since the initial interviews.
These items were considered important to accurately re-
flect resource use associated with HAE and its treatment.
A second set of cognitive debriefing interviews con-
firmed the relevance of revisions made to the HAE PRO
following the clinician input. Evidence from these inter-
views confirmed that the HAE PRO is a relevant, well
understood measure of HAE attack concepts. Several
minor edits implemented based on the interview findings
will further strengthen patient comprehension and reduce
the likelihood of confusion when completing the question-
naire in a real world setting.
The face and content validity of the HAE PRO has
been confirmed across four stages of development using
input from 110 HAE patients from six countries. Given
the global base of the sample the authors are confident
that the conceptual model used as the basis for develop-
ment of the instrument is representative of HAE patients’
experiences and the findings of the study are generalizable
across cultures. The culturally diverse sample that pro-
vided input, particularly in the cognitive debriefing stage
of the HAE PRO development supports the use of the
HAE PRO in a multi-national study. Throughout the
development process consideration was given to ensuring
items and response options were reflective of the attack
experience across countries and not simply specific to one
culture or healthcare system. The HAE PRO is considered
a content valid and appropriate tool for the long term as-
sessment of HAE attack symptoms and resource use in a
real world context.
Since development of the HAE PRO, two questionnaires
assessing health-related quality of life in HAE patients
have been developed, the HAE-QoL and the AE-QoL
[18, 19]. However, while both of these instruments are
well developed and specific to HAE (HAE-QoL) or re-
current angioedema including HAE (AE-QoL), neither
assesses all of the concepts identified in the concept
elicitation phase of this work and their aims are differ-
ent. The HAE-QoL, developed by Prior et al., assesses
very specific impacts of HAE on quality of life, but there is
no assessment of concepts specifically related to HAE at-
tacks including: triggers, warning signs, symptoms, attack
characteristics and treatments [19]. The AE-QoL, devel-
oped by Weller et al., is a very well developed tool that
focuses more on the impacts of angioedema and how
having the condition affects the patients, rather than asses-
sing specific HAE attack characteristics [18]. While these
instruments both have their interest to assess how HAE af-
fects patients, they are not considered for independent use
in the assessment of HAE attacks as a whole. As the aim of
this project was to develop a questionnaire that could be
used to assess all aspects of HAE in a real world context
the HAE PRO is considered the most appropriate instru-
ment to take forward to the proposed registry study.
While this was a robust, well-designed study certain
limitations in the study design and ability to make dis-
tinct conclusions should be recognized. While the HAE
PRO development process involved patients from across
a number of different countries, the country representa-
tion and patient involvement differed at each of the de-
velopment stages. This was partly intentional to ensure
representative input from a range of different cultures and
healthcare settings was achieved at the different phases of
HAE PRO development. However, this was also a factor
of the rare nature of HAE and the ability to recruit suffi-
cient numbers of independent patients in each country for
each phase of the instrument development. While there
were variations in the involvement of patients from each
of the countries represented at the different phases of the
research, the authors feel this allowed a greater cultural
representation in the HAE PRO development process and
findings indicated that concepts of importance to patients
were consistent across the countries. However, it is recog-
nized that this variation in country representation limits
the distinct conclusions that can be made about relevance
of concepts to each individual country of interest.
The face and content validity of the HAE PRO has
been confirmed through this extensive qualitative research
process. However, the measurement properties of the
HAE PRO have not been explored. Future additional re-
search could be conducted to confirm the measurement
properties of the HAE PRO. Furthermore, currently the
HAE PRO has been developed and culturally adapted for
use across seven different languages, further translation
and linguistic validation could be conducted to expand
the HAE PRO for use in additional language versions for
additional country settings.
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Conclusion
Input from HAE patients and expert clinicians has con-
tributed to the development of a strong, content-valid
questionnaire that assesses concepts important to HAE
patients globally. HAE patients across cultures consider
the HAE PRO a relevant and appropriate assessment of
concepts associated with HAE attacks and preventative
treatments. The HAE PRO can be considered a content-
valid and appropriate tool for the long-term assessment
of HAE attack symptoms and resource use in a real-
world context.
For further information about the HAE PRO please
contact Shire (haepro@shire.com).
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